{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:00:41Z","timestamp":1791295241999,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["23KFL021"],"award-info":[{"award-number":["23KFL021"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.heliyon.2023.e22016","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T22:38:37Z","timestamp":1699310317000},"page":"e22016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice"],"prefix":"10.1016","volume":"9","author":[{"given":"Yan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-883X","authenticated-orcid":false,"given":"Huida","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9 Suppl","key":"10.1016\/j.heliyon.2023.e22016_bib1","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am. J. Manag. Care"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22016_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1542\/pir.2019-0053","article-title":"Hyperlipidemia","volume":"41","author":"Stewart","year":"2020","journal-title":"Pediatr. Rev."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22016_bib3","first-page":"328","article-title":"HMG-CoA reductase inhibitors (Statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-An overview","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.heliyon.2023.e22016_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109416","article-title":"Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling","volume":"119","author":"Li","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e22016_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.31.10.942","article-title":"Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin","volume":"31","author":"Shin","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e22016_bib6","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1021\/acs.molpharmaceut.1c00305","article-title":"[18F]Atorvastatin pharmacokinetics and biodistribution in healthy female and male rats","volume":"18","author":"Clemente","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.heliyon.2023.e22016_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/892470","article-title":"Development and validation of an HPLC method for simultaneous quantification of clopidogrel bisulfate, its carboxylic acid metabolite, and atorvastatin in human plasma: application to a pharmacokinetic study","volume":"2015","author":"Croitoru","year":"2015","journal-title":"J Anal Methods Chem"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22016_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/chromsci\/bmaa126","article-title":"Pharmacokinetics and pharmacodynamic herb-drug interaction of piperine with atorvastatin in rats","volume":"59","author":"Thomas","year":"2021","journal-title":"J. Chromatogr. Sci."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e22016_bib9","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e22016_bib10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennern\u00e4s","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22016_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","article-title":"Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"81","author":"Lau","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e22016_bib12","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1021\/jf071797h","article-title":"Citrus limonoids: analysis, bioactivity, and biomedical prospects","volume":"55","author":"Manners","year":"2007","journal-title":"J. Agric. Food Chem."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22016_bib13","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.phymed.2015.08.013","article-title":"Citrus limonoid nomilin inhibits osteoclastogenesis in vitro by suppression of NFATc1 and MAPK signaling pathways","volume":"22","author":"Kimira","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.heliyon.2023.e22016_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.phrs.2016.09.038","article-title":"Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort?","volume":"118","author":"Mouly","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"15","key":"10.1016\/j.heliyon.2023.e22016_bib15","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1111\/jcmm.15484","article-title":"Nomilin targets the Keap1-Nrf2 signalling and ameliorates the development of osteoarthritis","volume":"24","author":"Xue","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22016_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1039\/C3FO60440C","article-title":"The functional evaluation of waste yuzu (Citrus junos) seeds","volume":"5","author":"Minamisawa","year":"2014","journal-title":"Food Funct."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e22016_bib17","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1039\/C9FO01481K","article-title":"Nomilin protects against cerebral ischemia-reperfusion induced neurological deficits and blood-brain barrier disruption via the Nrf2 pathway","volume":"10","author":"Shi","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.heliyon.2023.e22016_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/B978-0-12-407766-9.00018-3","article-title":"Nomilin as an anti-obesity and anti-hyperglycemic agent","volume":"91","author":"Sato","year":"2013","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.heliyon.2023.e22016_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113386","article-title":"Development of UPLC-MS\/MS method for studying the pharmacokinetic interactions of pexidartinib with antifungal drugs in rats","volume":"188","author":"Shi","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.heliyon.2023.e22016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113353","article-title":"Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS\/MS","volume":"187","author":"Xie","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e22016_bib21","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/jssc.202200185","article-title":"Ultra-high performance supercritical fluid chromatography-tandem mass spectrometry method for simultaneous determination of atorvastatin, 2-hydroxy atorvastatin, and tangeretin in rat plasma and its application to the pharmacokinetic study","volume":"45","author":"Li","year":"2022","journal-title":"J. Separ. Sci."},{"key":"10.1016\/j.heliyon.2023.e22016_bib22","volume":"vol. 66","year":"2001"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22016_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/bmc.3294","article-title":"A sensitive and high-throughput LC-MS\/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates","volume":"29","author":"Liu","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.heliyon.2023.e22016_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cbi.2015.02.022","article-title":"Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation","volume":"231","author":"Jiang","year":"2015","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22016_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/dmd.113.054783","article-title":"Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22016_bib26","first-page":"224","article-title":"A rapid, selective and sensitive UPLC-MS\/MS method for quantification of nomilin in rat plasma and its application in a pharmacokinetic study","volume":"82","author":"Cai","year":"2016","journal-title":"Planta Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22016_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1124\/dmd.118.084509","article-title":"Suppression of hepatic CYP3A4 expression and activity by 3-methylcholanthrene in humanized PXR-CAR-CYP3A4\/3A7 mice","volume":"47","author":"Crosby","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22016_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/toxsci\/kfu216","article-title":"Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration","volume":"143","author":"Jiang","year":"2015","journal-title":"Toxicol. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023092241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023092241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:26:40Z","timestamp":1791293200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023092241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2405844023092241"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22016","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e22016"}}